[go: up one dir, main page]

US20030045566A1 - Method of modulating microglial activation for the treatment of acute and chronic neurodegenerative disorders - Google Patents

Method of modulating microglial activation for the treatment of acute and chronic neurodegenerative disorders Download PDF

Info

Publication number
US20030045566A1
US20030045566A1 US10/274,587 US27458702A US2003045566A1 US 20030045566 A1 US20030045566 A1 US 20030045566A1 US 27458702 A US27458702 A US 27458702A US 2003045566 A1 US2003045566 A1 US 2003045566A1
Authority
US
United States
Prior art keywords
inhibiting
administration
human
lps
need
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/274,587
Inventor
Rand Posmantur
Lav Parvathenani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/274,587 priority Critical patent/US20030045566A1/en
Publication of US20030045566A1 publication Critical patent/US20030045566A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines

Definitions

  • the present invention comprises methods of treating various acute and chronic central nervous system disorders by the administration of FLAP or 5-lipoxygenase inhibitors.
  • Acute and chronic brain injuries can activate resident microglia (resident macrophage-like cells found in the central nervous system) as well as recruit peripheral immune cells to injured brain regions that can exacerbate neuronal damage. Inflammatory processes can induce cell death by (a) the release of proteases and free radicals that induce lipid peroxidation, (b) direct cytotoxic effects or (c) by the phagocytosis of sublethally injured neurons.
  • the attenuation of microglia and peripheral immune cell activation has been correlated with significant neuronal protection in pre-clinical studies of ischemia, traumatic brain injury, spinal cord injury and Alzheimer's disease.
  • Cycloxygenase (COX; prostagiandin H2 synthase) is responsible for the formation of prostaglandins and thomboxanes. See Versteeg, H. Van, van Bergen en Henegouwen, M. P. V., van Deventer, S. J. W. and Peppelenbosch, M. P. (1999). Cyclooxygenase-dependent signaling: molecular events and consequences. FEBS letters 445: 1-5.
  • Lipoxygenase is responsible for the conversion of arachidonic acid to leukotrienes. Lipoxygenases and Their Metabolites, Plenum Press, New York Eds. Nigam and Pace-Asciak. (1999). It is hypothesized that prostaglandins are an important step in transducing immune stimuli into CNS responses.
  • COX-1 constitutuitively expressed
  • COX-2 induction in response to immune stimuli. It has been established that COX-1 and COX-2 are found to be induced and constituitively expressed in peripheral immune cells as well as brain, with neuronal expression of COX-2 being enhanced following various CNS insults including cerebral ischemia.
  • lipoxygenases or subsequent metabolites including hydroxyeicosatetraenoic acids (HETEs), leukotrienes, lipoxines, and hepoxilins
  • HETEs hydroxyeicosatetraenoic acids
  • lipoxines lipoxines
  • hepoxilins hydroxyeicosatetraenoic acids
  • prostaglandins and COX-2 in modulating inflammation and pain has been well elucidated, the importance of LOX enzymes (specifically 5-LOX or 5-lipoxygenase) in brain following injury is still unresolved. Simon, L. S. Role and regulation of cyclooxygenase-2 during inflammation American Journal of Medicine 106: 37S-42S (1999).
  • a method of modulating or inhibiting microglia activation comprising the administration to a human in need thereof a compound capable of inhibiting 5-LOX.
  • a method of modulating or inhibiting microglia activation comprising the administration to a human in need thereof a compound capable of selectively inhibiting 5-LOX over COX-2.
  • a method of modulating or inhibiting microglia activation comprising the administration to a human in need thereof a compound capable of inhibiting FLAP.
  • a method of modulating or inhibiting microglia activation comprising the administration to a human in need thereof para-REV5901 (L-655,238), Bay-x-1005, ML-3000, NDGA or ZILEUTON®.
  • a method of inhibiting the release of pro-inflammatory substances from activated microglial cells comprising the administration to a human in need thereof a compound capable of inhibiting 5-LOX.
  • a method of inhibiting the release of pro-inflammatory substances from activated microglial cells comprising the administration to a human in need thereof a compound capable of selectively inhibiting 5-LOX over COX-2.
  • a method of inhibiting the release of pro-inflammatory substances from activated microglial cells comprising the administration to a human in need thereof a compound capable of inhibiting FLAP.
  • a method of inhibiting the release of pro-inflammatory substances from activated microglial cells comprising the administration to a human in need thereof para-REV5901 (L-655,238), Bay-x-1005, ML-3000, NDGA or ZILEUTONO®.
  • a method of treating Alzheimer's disease, brain ischemia, traumatic brain injury, Parkinson's Disease, Multiple Sclerosis, ALS, subarachnoid hemorrhage or other disorders associated with excessive production of inflammatory mediators in the brain comprising the administration to a human in need thereof a compound capable of inhibiting 5-LOX.
  • a method of treating Alzheimer's disease, brain ischemia, traumatic brain injury, Parkinson's Disease, Multiple Sclerosis, ALS, subarachnoid hemorrhage or other disorders associated with excessive production of inflammatory mediators in the brain comprising the administration to a human in need thereof a compound capable of 5-LOX over COX-2.
  • a method of treating Alzheimer's disease, brain ischemia, traumatic brain injury, Parkinson's Disease, Multiple Sclerosis, ALS, subarachnoid hemorrhage or other disorders associated with excessive production of inflammatory mediators in the brain comprising the administration to a human in need thereof a compound capable of inhibiting FLAP.
  • a method of treating Alzheimer's disease, brain ischemia, traumatic brain injury, Parkinson's Disease, Multiple Sclerosis, ALS, subarachnoid hemorrhage or other disorders associated with excessive production of inflammatory mediators in the brain comprising the administration to a human in need thereof para-REV5901 (L-655,238), Bay-x-1005, ML-3000, NDGA or ZILEUTON®.
  • a method of attenuating degradation of I ⁇ B ⁇ comprising the administration to a human in need thereof a compound capable of inhibiting 5-LOX.
  • a method of attenuating degradation of I ⁇ B ⁇ comprising the administration to a human in need thereof a compound capable of selectively inhibiting 5-LOX over COX-2.
  • a method of attenuating degradation of I ⁇ B ⁇ comprising the administration to a human in need thereof a compound capable of inhibiting FLAP.
  • a method of attenuating degradation of I ⁇ B ⁇ comprising the administration to a human in need thereof para-REV5901 (L-655,238), Bay-x-1005, ML-3000, NDGA or ZILEUTON®.
  • a method of inhibiting nuclear translocation of the NF- ⁇ B active complex comprising the administration to a human in need thereof a compound capable of inhibiting 5-LOX.
  • a method of inhibiting nuclear translocation of the NF- ⁇ B active complex comprising the administration to a human in need thereof a compound capable of selectively inhibiting 5-LOX over COX-2.
  • a method of inhibiting nuclear translocation of the NF- ⁇ B active complex comprising the administration to a human in need thereof a compound capable of inhibiting FLAP.
  • a method of inhibiting nuclear translocation of the NF- ⁇ B active complex comprising the administration to a human in need thereof para-REV5901 (L-655,238), Bay-x-1005, ML-3000, NDGA or ZILEUTON®.
  • a compound capable of selectively inhibiting 5-LOX over COX-2 means a compound having 1 to 500-fold or more, particularly 1 to 50-fold and more particularly 1 to 10-fold selectivity for 5-LOX over COX-2 as measured by the ability to attenuate the production of arachidonic acid metabolites from cellular suspensions (derived from blood or cell lines) stimulated with ionophore A23187 as previously described (Salari et al., 1984, Prostaglandins and Leukotrienes, Vol 13: 53-60; Menard et al., 1990, Br. J. Pharmacol 100: 15-20) incorporated by reference herein.
  • 5-HETE and LTB4 are arachidonic acid metabolites derived from 5-LOX and 12-hydroxy-heptadecatrienoic (HHT) is an arachidonic acid metabolite for cycloxygenase activity.
  • HHT 12-hydroxy-heptadecatrienoic
  • COX-2 can be specifically assessed by the ability to attenuate the production of the arachidonic acid metabolite, PGE2, from cellular suspensions (derived from blood or cell lines) stimulated with the LPS (Laufer et al., 1999, Inflammation Research, 48: 133-138; Horton et al., 1999; Anal Biochim 271:18-28).
  • FLAP means 5-LOX activating protein.
  • Compounds that inhibit FLAP can be measured by the ability to inhibit photoaffinity labeling of a source of purified FLAP (i.e. rat or human).
  • FLAP inhibitors are confirmed if there is a correlation in the inhibition of leukotriene synthesis in vitro cell based assays (i.e. Human PMN leukotriene synthesis) (Evans et al., 1991, Molecular Pharmacology 40:22-27).
  • inflammatory mediators in the brain includes but is not limited to cytokines, chemokines, prostaglandins and leukotrienes.
  • pro-inflammatory substances includes but is not limited to TNF-alpha, nitrite, NO, IL-6, IL-1, 5-HETE, LTB4, LTA4 and other inflammatory substances.
  • Bay-x-1005 (C 23 H 23 NO 3 ) is a selective inhibitor of FLAP. See Drugs Fut 1995, 20:996 and Drugs Fut 2000 25(10):1084.
  • ML-3000 is an inhibitor of both COX and LOX. See Drugs Fut 1995 20:1007 and Drugs Fut 25(10):1093.
  • Cytosolic Ca2+dependent type IV phospholipase A2 (CPLA2) generates intracellular arachidonic acid (AA). AA is converted to pro-inflammatory prostaglandins, thromboxanes, and leukotrienes by either cycloxygenases (COX) or lipoxygenases (LOX).
  • COX cycloxygenases
  • LOX lipoxygenases
  • cytosolic phospholipase A2 (cPLA 2 ) is one of the major enzymes involved in the generation of AA
  • LPS lipopolysaccharide
  • Indirect immunofluorescence with a cPLA 2 specific monoclonal antibody revealed that cPLA 2 was localized primarily in the cytosol in untreated cells.
  • cPLA 2 redistributed to form punctate bodies within 15 minutes and returned to a control immuno-staining pattern by 60 minutes (the transient redistribution of cPLA2 to punctate bodies is an intracellular event associated with higher activity).
  • cPLA 2 The activity of cPLA 2 can also be enhanced by phosphorylation (Lin et al., 1993). Phosphorylated cPLA 2 can be distinguished from unphosphorylated cPLA 2 by migration on SDS-PAGE. Immunoblotting revealed that cPLA 2 in control cells was predominately unphosphorylated. Following LPS challenge cPLA 2 shifted to a phosphorylated form between 10-20 minutes post-challenge.
  • CPLA2 inhibitors i.e., ATFMK (arachidonyltrifluoromethyl ketone) and BMS 229724 have shown significant dose-dependent inhibition of TNF-alpha and nitrite release in LPS activated microglia.
  • COX-2 inhibitors rofecoxib (VIOXX®) and celecoxib (CELEBREX®) had no significant effect on pro-inflammatory release on activated microglia.
  • para-REV5901 ( ⁇ -pentyl-4-(3-quinolinylmethyl)benzenemethanol) a 5-LOX activating protein inhibitor and NDGA (nordihdroguaiaretic acid) a 5-LOX inhibitor, dose dependently inhibited TNF-alpha release and nitrite to near control levels following LPS challenge in microglia cells.
  • 5-LOX via CPLA2, AA, and NF- ⁇ B signaling
  • CPLA2, AA, and NF- ⁇ B signaling is a preferential target over COX-2 in modulating or inhibiting microglia activation. Consequently, modulating either 5-LOX alone or in conjunction with COX-2 could have direct effects in enhancing neuronal survival in acute and chronic CNS diseases including Alzheimer's disease, brain ischemia, traumatic brain injury, Parkinson's Disease, Multiple Sclerosis, ALS, and subarachnoid hemorrhage.
  • Rat microglia were prepared from two day old rat pups. Pup brains were removed and the meninges were gently removed. Once sufficient amount of brains were collected, brains were minced with a blunt scissors (10 times) and transferred to a 15 ml conical tube with a pasteur pipette and titurated 25 times. Dissociated cells were then centrifuged at 1000 RPM for 10 minutes (RT). The supernatant was removed and 2 mls of fresh media was added. The resultant cell suspension was titurated 10 times. Following titration the cell suspension was plated in a T175 cm 2 culture flasks at a density of 4 brains per flask in 25 mls.
  • MEM media was used for the experiments, supplemented with 10% FBS, 100 i.u.penicillin, 100 i.u.streptomycin and L-Glutamine.
  • Microglia were isolated on day 14 by shaking on an orbital rotation shaker. The purity of the cultures was 98-100% as determined by immunostaining with ED-40 antibody.
  • Endotoxin (LPS) at a concentration of a 100 ng/ml were used for activation of rat microglia cells. This concentration had previously shown to be effective in inducing TNF-alpha and Nitrite release. All assays were performed in 48 well plates (Becton Dickinson) at ⁇ 2 ⁇ 10 5 cells or 0.5 ⁇ 10 5 per 1 ml per well in 10% MEM media. Microglia cells were pre-incubated 1 hr prior to LPS challenge with either vehicle (0.1% DMSO) or test compound in DMEM containing 10% FBS (microglia) or RPMI containing 10% FBS (THP-1 monocytes). Supernatants from LPS activated rat microglia were collected at 24 hrs post-LPS challenge.
  • Nitrite assay was performed in a 96 well plate using a Modified Griess Reagent (Sigma). In brief, a 100 ul of Modified Griess Reagent was added to a 100 ul of collected supernatant. Samples were read at a wavelength of 540 nM. All values were calculated against a NaNO2 standard curve.
  • Immunoblotting was carried out as described previously (Parvathenani et al., 2000). Briefly 25 ⁇ g of protein was fractionated on a 4-20% tris-glycine gel (NOVEX, Calif.) and transferred to PVDF membrane (NOVEX, Calif.). The membrane was probed with a polyclonal antibody specific for I ⁇ B ⁇ . To distinguish between the phosphorylated and non-phosphorylated forms of cPLA 2 , 50 ⁇ g of protein was run on an 8% tris-glycine gel (Novex, Calif.) for 4.5 hours at 125V, transferred and probed with a monoclonal antibody specific for cPLA 2 .
  • NDGA nodecyl-N-(nordihdroguaiaretic acid), para-REV5901 (( ⁇ -pentyl-4-(3-quinolinylmethyl)benzenemethanol), ATFMK (arachidonyltrifluoromethyl ketone) was obtained from Calbiochem (San Diego, Calif.). Ibuprofen and LPS was purchased from Sigma (St. Louis, Mo.). BMS 229724 was synthesized at Bristol-Myers Squibb. NF- ⁇ B SN50 and (E)3-((4-t-Butylphenyl)sulfonyl)-2-propenenitrile (BAY-11-7085) were obtained from Biomol (Plymouth Meeting, Pa.).
  • FIGS. 1 A-E Legend
  • Microglia were treated with 100 ng/ml of LPS for various periods of time following which A-D.
  • cPLA 2 distribution was assessed by indirect immunofluorescence ( 1 A) control , ( 1 B) LPS-15 min, ( 1 C) LPS-15 min, ( 1 D) LPS-60 min, ( 1 E) whole cell lysates were prepared and run on SDS-PAGE, transferred and probed with a cPLA 2 antibody.
  • FIGS. 2 A-D Legend
  • 5-lipoxygnease inhibitor (NDGA, 2 A) and 5-lipoxygenase activating protein inhibitor (para-REV5901, 2 B) significantly inhibited TNF-alpha release, however, COX-2 inhibitors Ibuprofen ( 2 C), Vioxx ( 2 D), and Celebrex ( 2 D) failed to produce any reduction in TNF-alpha release in rat primary microglia cells following LPS activation.
  • FIGS. 3 A-B Legend
  • cPLA2 inhibitors ATFMK ( 3 A) and BMS-229724 ( 3 B) significantly inhibited TNF-alpha release in rat primary microglia cells following LPS activation.
  • FIGS. 4 A-C Legend
  • FIGS. 5 A-B Legend
  • FIGS. 6 A-C Legend
  • FIGS. 7 A-D Legend

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides methods of modulating or inhibiting microglia activation comprising the administration of a compound capable of inhibiting 5-LOX, FLAP, attenuating degradation of IκBα or inhibiting nuclear translocation of the NF-κB active complex for the treatment of Alzheimer's disease, brain ischemia, traumatic brain injury, Parkinson's Disease, Multiple Sclerosis, ALS, subarachnoid hemorrhage or other disorders associated with excessive production of inflammatory mediators in the brain.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application is a divisional application of nonprovisional application U.S. Ser. No. 09/899,657 filed Jul. 5, 2001 which claims priority from provisional applications U.S. Ser. No. 60/218,085 filed Jul. 13, 2000 and U.S. Ser. No. 60/261,332 filed Jan. 12, 2001.[0001]
    • FIELD OF THE INVENTION
  • The present invention comprises methods of treating various acute and chronic central nervous system disorders by the administration of FLAP or 5-lipoxygenase inhibitors. [0002]
    • BACKGROUND OF THE INVENTION
  • Acute and chronic brain injuries can activate resident microglia (resident macrophage-like cells found in the central nervous system) as well as recruit peripheral immune cells to injured brain regions that can exacerbate neuronal damage. Inflammatory processes can induce cell death by (a) the release of proteases and free radicals that induce lipid peroxidation, (b) direct cytotoxic effects or (c) by the phagocytosis of sublethally injured neurons. The attenuation of microglia and peripheral immune cell activation has been correlated with significant neuronal protection in pre-clinical studies of ischemia, traumatic brain injury, spinal cord injury and Alzheimer's disease. [0003]
  • Oxygenase enzymes like cycloxygenase and lipoxygenase can initiate the conversion of arachidonic acid to physiological important metabolites. Cycloxygenase (COX; prostagiandin H2 synthase) is responsible for the formation of prostaglandins and thomboxanes. See Versteeg, H. Van, van Bergen en Henegouwen, M. P. V., van Deventer, S. J. W. and Peppelenbosch, M. P. (1999). Cyclooxygenase-dependent signaling: molecular events and consequences. [0004] FEBS letters 445: 1-5. Lipoxygenase is responsible for the conversion of arachidonic acid to leukotrienes. Lipoxygenases and Their Metabolites, Plenum Press, New York Eds. Nigam and Pace-Asciak. (1999). It is hypothesized that prostaglandins are an important step in transducing immune stimuli into CNS responses. There are two known isozymes of COX currently known COX-1 (constituitively expressed) and COX-2 (induction in response to immune stimuli). It has been established that COX-1 and COX-2 are found to be induced and constituitively expressed in peripheral immune cells as well as brain, with neuronal expression of COX-2 being enhanced following various CNS insults including cerebral ischemia. Tomimoto, H., Akiguchi, I. Watkita, H., Lin, J. X., Budka, H. Cyclooxygenase-2 is also induced in microglia during chronic cerebral ischemia in humans. Acta Neuropathol (Berl) 1: 26-30 (2000).
  • However, little is known about the role of lipoxygenases (or subsequent metabolites including hydroxyeicosatetraenoic acids (HETEs), leukotrienes, lipoxines, and hepoxilins) in regulating brain inflammation or neurodegeneration. There are currently four known human lipoxygenases (5, 8, 12, and 15-lipoxygenase). All isoforms share a common substrate as well as oxygenase activity but differ greatly in sequence. Although, the role of prostaglandins and COX-2 in modulating inflammation and pain has been well elucidated, the importance of LOX enzymes (specifically 5-LOX or 5-lipoxygenase) in brain following injury is still unresolved. Simon, L. S. Role and regulation of cyclooxygenase-2 during inflammation [0005] American Journal of Medicine 106: 37S-42S (1999).
    • SUMMARY OF THE INVENTION
  • Thus, according to a first embodiment of a first aspect of the present invention is provided a method of modulating or inhibiting microglia activation comprising the administration to a human in need thereof a compound capable of inhibiting 5-LOX. [0006]
  • According to another embodiment of the first aspect of the present invention is provided a method of modulating or inhibiting microglia activation comprising the administration to a human in need thereof a compound capable of selectively inhibiting 5-LOX over COX-2. [0007]
  • According to another embodiment of the first aspect of the present invention is provided a method of modulating or inhibiting microglia activation comprising the administration to a human in need thereof a compound capable of inhibiting FLAP. [0008]
  • According to another embodiment of the first aspect of the present invention is provided a method of modulating or inhibiting microglia activation comprising the administration to a human in need thereof para-REV5901 (L-655,238), Bay-x-1005, ML-3000, NDGA or ZILEUTON®. [0009]
  • According to a first embodiment of a second aspect of the present invention is provided a method of inhibiting the release of pro-inflammatory substances from activated microglial cells comprising the administration to a human in need thereof a compound capable of inhibiting 5-LOX. [0010]
  • According to another embodiment of a second aspect of the present invention is provided a method of inhibiting the release of pro-inflammatory substances from activated microglial cells comprising the administration to a human in need thereof a compound capable of selectively inhibiting 5-LOX over COX-2. [0011]
  • According to another embodiment of a second aspect of the present invention is provided a method of inhibiting the release of pro-inflammatory substances from activated microglial cells comprising the administration to a human in need thereof a compound capable of inhibiting FLAP. [0012]
  • According to another embodiment of a second aspect of the present invention is provided a method of inhibiting the release of pro-inflammatory substances from activated microglial cells comprising the administration to a human in need thereof para-REV5901 (L-655,238), Bay-x-1005, ML-3000, NDGA or ZILEUTONO®. [0013]
  • According to a first embodiment of a third aspect of the present invention is provided a method of treating Alzheimer's disease, brain ischemia, traumatic brain injury, Parkinson's Disease, Multiple Sclerosis, ALS, subarachnoid hemorrhage or other disorders associated with excessive production of inflammatory mediators in the brain comprising the administration to a human in need thereof a compound capable of inhibiting 5-LOX. [0014]
  • According to another embodiment of a third aspect of the present invention is provided a method of treating Alzheimer's disease, brain ischemia, traumatic brain injury, Parkinson's Disease, Multiple Sclerosis, ALS, subarachnoid hemorrhage or other disorders associated with excessive production of inflammatory mediators in the brain comprising the administration to a human in need thereof a compound capable of 5-LOX over COX-2. [0015]
  • According to another embodiment of a third aspect of the present invention is provided a method of treating Alzheimer's disease, brain ischemia, traumatic brain injury, Parkinson's Disease, Multiple Sclerosis, ALS, subarachnoid hemorrhage or other disorders associated with excessive production of inflammatory mediators in the brain comprising the administration to a human in need thereof a compound capable of inhibiting FLAP. [0016]
  • According to another embodiment of a third aspect of the present invention is provided a method of treating Alzheimer's disease, brain ischemia, traumatic brain injury, Parkinson's Disease, Multiple Sclerosis, ALS, subarachnoid hemorrhage or other disorders associated with excessive production of inflammatory mediators in the brain comprising the administration to a human in need thereof para-REV5901 (L-655,238), Bay-x-1005, ML-3000, NDGA or ZILEUTON®. [0017]
  • According to a first embodiment of a fourth aspect of the present invention is provided a method of attenuating degradation of IκBα comprising the administration to a human in need thereof a compound capable of inhibiting 5-LOX. [0018]
  • According to another embodiment of a fourth aspect of the present invention is provided a method of attenuating degradation of IκBα comprising the administration to a human in need thereof a compound capable of selectively inhibiting 5-LOX over COX-2. [0019]
  • According to another embodiment of a fourth aspect of the present invention is provided a method of attenuating degradation of IκBα comprising the administration to a human in need thereof a compound capable of inhibiting FLAP. [0020]
  • According to another embodiment of a fourth aspect of the present invention is provided a method of attenuating degradation of IκBα comprising the administration to a human in need thereof para-REV5901 (L-655,238), Bay-x-1005, ML-3000, NDGA or ZILEUTON®. [0021]
  • According to a first embodiment of a fifth aspect of the present invention is provided a method of inhibiting nuclear translocation of the NF-κB active complex comprising the administration to a human in need thereof a compound capable of inhibiting 5-LOX. [0022]
  • According to another embodiment of a fifth aspect of the present invention is provided:a method of inhibiting nuclear translocation of the NF-κB active complex comprising the administration to a human in need thereof a compound capable of selectively inhibiting 5-LOX over COX-2. [0023]
  • According to another embodiment of a fifth aspect of the present invention is provided a method of inhibiting nuclear translocation of the NF-κB active complex comprising the administration to a human in need thereof a compound capable of inhibiting FLAP. [0024]
  • According to another embodiment of a fifth aspect of the present invention is provided a method of inhibiting nuclear translocation of the NF-κB active complex comprising the administration to a human in need thereof para-REV5901 (L-655,238), Bay-x-1005, ML-3000, NDGA or ZILEUTON®. [0025]
  • Other embodiments of the invention comprise two or more embodiments or elements thereof suitably combined. [0026]
  • Yet other embodiments and aspects of the invention will be apparent according to the description provided below. [0027]
    • DETAILED DESCRIPTION OF THE INVENTION
  • As used herein “a compound capable of selectively inhibiting 5-LOX over COX-2” means a compound having 1 to 500-fold or more, particularly 1 to 50-fold and more particularly 1 to 10-fold selectivity for 5-LOX over COX-2 as measured by the ability to attenuate the production of arachidonic acid metabolites from cellular suspensions (derived from blood or cell lines) stimulated with ionophore A23187 as previously described (Salari et al., 1984, Prostaglandins and Leukotrienes, Vol 13: 53-60; Menard et al., 1990, Br. J. Pharmacol 100: 15-20) incorporated by reference herein. For instance, 5-HETE and LTB4 are arachidonic acid metabolites derived from 5-LOX and 12-hydroxy-heptadecatrienoic (HHT) is an arachidonic acid metabolite for cycloxygenase activity. Alternatively, COX-2 can be specifically assessed by the ability to attenuate the production of the arachidonic acid metabolite, PGE2, from cellular suspensions (derived from blood or cell lines) stimulated with the LPS (Laufer et al., 1999, Inflammation Research, 48: 133-138; Horton et al., 1999; Anal Biochim 271:18-28). [0028]
  • As used herein “FLAP” means 5-LOX activating protein. Compounds that inhibit FLAP can be measured by the ability to inhibit photoaffinity labeling of a source of purified FLAP (i.e. rat or human). In addition, FLAP inhibitors are confirmed if there is a correlation in the inhibition of leukotriene synthesis in vitro cell based assays (i.e. Human PMN leukotriene synthesis) (Evans et al., 1991, Molecular Pharmacology 40:22-27). [0029]
  • As used herein “inflammatory mediators in the brain” includes but is not limited to cytokines, chemokines, prostaglandins and leukotrienes. [0030]
  • As used herein “pro-inflammatory substances” includes but is not limited to TNF-alpha, nitrite, NO, IL-6, IL-1, 5-HETE, LTB4, LTA4 and other inflammatory substances. [0031]
  • Bay-x-1005 (C[0032] 23H23NO3) is a selective inhibitor of FLAP. See Drugs Fut 1995, 20:996 and Drugs Fut 2000 25(10):1084.
    Figure US20030045566A1-20030306-C00001
  • ML-3000 is an inhibitor of both COX and LOX. See [0033] Drugs Fut 1995 20:1007 and Drugs Fut 25(10):1093.
    Figure US20030045566A1-20030306-C00002
  • REV5901-para-isomer (L-655,238-IC50=0.1 uM-5-LOX) is a selective 5-lipoxygenase activating protein inhibitor (FLAP) with a quinoline structure. It has been reported that FLAP inhibitors with this basic chemical structure interfere with 5-LOX and FLAP protein interactions preventing a required cellular translocation of 5-LOX. Moreover, it has been shown that compounds with the quinoline chemical structure do not affect other routes of arachidonic acid metabolism including known cycloxygenase and other lipoxygenases proteins (Evans et al., 1991, Molecular Pharmacology 40:22-27; Hutchinson, A. W. 1991, Trend in Pharmacological Studies, 12: 68-70). [0034]
  • NDGA is a selective 5-lipoxygenese over cycloxgenase inhibitor (IC50=0.2 uM-5-LOX, IC50=100 uM-COX)-Salari et al, 1984. [0035]
  • We have discovered that indirectly or directly inhibiting 5-lipoxygenase can preferentially attenuate pro-inflammatory cytokine release from activated rat microglia cells in comparison to COX-2 inhibition. While not intending to limit the scope of the invention to any particular mechanism the following description is provided. Cytosolic Ca2+dependent type IV phospholipase A2 (CPLA2) generates intracellular arachidonic acid (AA). AA is converted to pro-inflammatory prostaglandins, thromboxanes, and leukotrienes by either cycloxygenases (COX) or lipoxygenases (LOX). [0036]
  • Since cytosolic phospholipase A2 (cPLA[0037] 2) is one of the major enzymes involved in the generation of AA, the effect of lipopolysaccharide (LPS) on cPLA2 was determined. Indirect immunofluorescence with a cPLA2 specific monoclonal antibody revealed that cPLA2 was localized primarily in the cytosol in untreated cells. Upon stimulation with LPS, cPLA2 redistributed to form punctate bodies within 15 minutes and returned to a control immuno-staining pattern by 60 minutes (the transient redistribution of cPLA2 to punctate bodies is an intracellular event associated with higher activity). The activity of cPLA2 can also be enhanced by phosphorylation (Lin et al., 1993). Phosphorylated cPLA2 can be distinguished from unphosphorylated cPLA2 by migration on SDS-PAGE. Immunoblotting revealed that cPLA2 in control cells was predominately unphosphorylated. Following LPS challenge cPLA2 shifted to a phosphorylated form between 10-20 minutes post-challenge. Importantly, CPLA2 inhibitors, i.e., ATFMK (arachidonyltrifluoromethyl ketone) and BMS 229724 have shown significant dose-dependent inhibition of TNF-alpha and nitrite release in LPS activated microglia. The redistribution and phosphorylation of cPLA2 as well as, the attenuation of TNF-alpha and nitrite by cPLA2 inhibitors provide several lines of evidence for the activation of cPLA2 in LPS treated microglia.
    Figure US20030045566A1-20030306-C00003
  • COX-2 inhibitors rofecoxib (VIOXX®) and celecoxib (CELEBREX®) had no significant effect on pro-inflammatory release on activated microglia. Importantly, para-REV5901 ((α-pentyl-4-(3-quinolinylmethyl)benzenemethanol) a 5-LOX activating protein inhibitor and NDGA (nordihdroguaiaretic acid) a 5-LOX inhibitor, dose dependently inhibited TNF-alpha release and nitrite to near control levels following LPS challenge in microglia cells. [0038]
  • To further validate the role of 5-LOX in pro-inflammatory cytokine release transcriptional regulators of TNF-alpha and NO were examined. Lipoxygenases can activate NFκB mediated transcription via the generation of reactive oxygen intermediates (Lee et al., 1997; Bonizzi et al., 1999). Both the TNFα gene and inducible nitric oxide synthase (iNOS) gene contain NF-κB binding elements in their promoter sequences and activation of NF-κB is crucial for gene transcription (Goldfeld et al., 1990; Drouet et al., 1991; Xie et al., 1994). Hence the effects of inhibiting NF-κB mediated transcription using two distinct inhibitors was assessed with BAY 11-7085 an irreversible inhibitor of IκBα phosphorylation ([IC[0039] 50-10 μM] a biochemical event associated NF-κB activity) and NF-κB SN-50 a cell permeable peptide which inhibits translocation of NF-κB active complex into the nucleus (a required intracellular event associated with NF-κB activity; Lin et al., 1995; Pierce et al., 1997). Both BAY 11-7085 and NF-κB SN-50 inhibited LPS induced TNFα and NO release to control levels.
  • To further characterize the involvement of NF-κB in microglial signaling, the effect of LPS on the degradation of IκBα and NF-κB (p65) translocation from the cytosol to the nucleus was also determined. It was observed that IκBα was rapidly degraded within 20 minutes following LPS activation and reappeared to control levels by 60 minutes. Consistent with these observations, indirect immunofluorecence with a p65 antibody indicated that in control cells p65 was primarily localized in the cytosol, but after stimulation with LPS p65 rapidly translocated to the nucleus. These results demonstrate that NF-κB mediated transcription can play a role in microglia activation. [0040]
  • To determine whether cPLA[0041] 2 and 5-LOX regulate TNFα and NO release by influencing NF-κB activation, the effects of cPLA2 and 5-LOX inhibitors on IκBα degradation and nuclear translocation of NF-κB were examined. ATFMK and para-REV5901 attenuated the degradation of IκBα (following LPS stimulation. ATFMK and para-REV5901 also delayed the translocation of NF-κB into the nucleus. These results demonstrate that both cPLA2 and 5-LOX inhibitors attenuate the release of TNFα and NO by delaying IκBα degradation and interfering with NF-κB activation.
  • These data collectively represent that 5-LOX (via CPLA2, AA, and NF-κB signaling) is a preferential target over COX-2 in modulating or inhibiting microglia activation. Consequently, modulating either 5-LOX alone or in conjunction with COX-2 could have direct effects in enhancing neuronal survival in acute and chronic CNS diseases including Alzheimer's disease, brain ischemia, traumatic brain injury, Parkinson's Disease, Multiple Sclerosis, ALS, and subarachnoid hemorrhage. [0042]
  • Lin L L, Wartmann M, Lin A Y, Knopf J L, Seth A, Davis R J (1993) cPLA2 is phosphorylated and activated by MAP kinase. Cell 72:269-278. [0043]
  • Lee S, Felts K A, Parry G C, Armacost L M, Cobb R R (1997) Inhibition of 5-lipoxygenase blocks IL-1 beta-induced vascular adhesion molecule-1 gene expression in human endothelial cells. J Immunol 158:3401-3407. [0044]
  • Bonizzi G, Piette J, Schoonbroodt S, Greimers R, Havard L, Merville M P, Bours V (1999) Reactive oxygen intermediate-dependent NF-kappaB activation by interleukin-1beta requires 5-lipoxygenase or NADPH oxidase activity. Mol Cell Biol 19:1950-1960. [0045]
  • Goldfeld A E, Doyle C, Maniatis T (1990) Human tumor necrosis factor alpha gene regulation by virus and lipopolysaccharide. Proc Natl Acad Sci U S A 87:9769-9773. [0046]
  • Drouet C, Shakhov A N, Jongeneel C V (1991) Enhancers and transcription factors controlling the inducibility of the tumor necrosis factor-alpha promoter in primary macrophages. J Immunol 147:1694-1700. [0047]
  • Xie Q W, Kashiwabara Y, Nathan C (1994) Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. J Biol Chem 269:4705-4708. [0048]
  • Lin Y Z, Yao S Y, Veach R A, Torgerson T R, Hawiger J (1995) Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem 270:14255-14258. [0049]
  • Pierce J W, Schoenleber R, Jesmok G, Best J, Moore S A, Collins T. Gerritsen M E (1997) Novel inhibitors. of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem 272:21096-21103. [0050]
  • Isolation of Microglia from Rat Brains: [0051]
  • Rat microglia were prepared from two day old rat pups. Pup brains were removed and the meninges were gently removed. Once sufficient amount of brains were collected, brains were minced with a blunt scissors (10 times) and transferred to a 15 ml conical tube with a pasteur pipette and titurated 25 times. Dissociated cells were then centrifuged at 1000 RPM for 10 minutes (RT). The supernatant was removed and 2 mls of fresh media was added. The resultant cell suspension was titurated 10 times. Following titration the cell suspension was plated in a T175 cm[0052] 2 culture flasks at a density of 4 brains per flask in 25 mls. MEM media was used for the experiments, supplemented with 10% FBS, 100 i.u.penicillin, 100 i.u.streptomycin and L-Glutamine. Microglia were isolated on day 14 by shaking on an orbital rotation shaker. The purity of the cultures was 98-100% as determined by immunostaining with ED-40 antibody.
  • Rat Microglia Cell Activation and Drug Exposure [0053]
  • Endotoxin (LPS) at a concentration of a 100 ng/ml were used for activation of rat microglia cells. This concentration had previously shown to be effective in inducing TNF-alpha and Nitrite release. All assays were performed in 48 well plates (Becton Dickinson) at ˜2×10[0054] 5 cells or 0.5×105 per 1 ml per well in 10% MEM media. Microglia cells were pre-incubated 1 hr prior to LPS challenge with either vehicle (0.1% DMSO) or test compound in DMEM containing 10% FBS (microglia) or RPMI containing 10% FBS (THP-1 monocytes). Supernatants from LPS activated rat microglia were collected at 24 hrs post-LPS challenge.
  • TNF-alpha ELISA [0055]
  • Collected supernatants were assayed for TNF-alpha using a Pharmingen OPtEIA Rat (microglia). [0056]
  • Nitrite Assay [0057]
  • Nitrite assay was performed in a 96 well plate using a Modified Griess Reagent (Sigma). In brief, a 100 ul of Modified Griess Reagent was added to a 100 ul of collected supernatant. Samples were read at a wavelength of 540 nM. All values were calculated against a NaNO2 standard curve. [0058]
  • Immunofluorescence [0059]
  • Cells were washed once with PBS, fixed and permeabilized with ice cold methanol (100%) for 5 minutes and washed 3× in PBS for 10 min. The cover slips were blocked for 1 hour in 10% serum/PBS (serum derived from animal in which secondary antibody was generated), incubated for 2-3 hours in primary antibody solution (1:50 dilution in 1.5% serum/PBS) and washed 3× in PBS for 10 min. Secondary antibody linked to fluorescein was applied for one hour (1:100 dilution in 1.5% serum/PBS) and washed 3× in PBS for 10 min. If the nucleus was stained, the cells were incubated for 15 minutes with DAPI (1:10000) at 37° C. and washed. The coverslips were then mounted onto glass slides using mounting media and viewed under a fluorescence microscope. [0060]
  • Immunoblotting [0061]
  • Immunoblotting was carried out as described previously (Parvathenani et al., 2000). Briefly 25 μg of protein was fractionated on a 4-20% tris-glycine gel (NOVEX, Calif.) and transferred to PVDF membrane (NOVEX, Calif.). The membrane was probed with a polyclonal antibody specific for IκBα. To distinguish between the phosphorylated and non-phosphorylated forms of cPLA[0062] 2, 50 μg of protein was run on an 8% tris-glycine gel (Novex, Calif.) for 4.5 hours at 125V, transferred and probed with a monoclonal antibody specific for cPLA2.
  • Materials [0063]
  • NDGA (nordihdroguaiaretic acid), para-REV5901 ((α-pentyl-4-(3-quinolinylmethyl)benzenemethanol), ATFMK (arachidonyltrifluoromethyl ketone) was obtained from Calbiochem (San Diego, Calif.). Ibuprofen and LPS was purchased from Sigma (St. Louis, Mo.). [0064] BMS 229724 was synthesized at Bristol-Myers Squibb. NF-κB SN50 and (E)3-((4-t-Butylphenyl)sulfonyl)-2-propenenitrile (BAY-11-7085) were obtained from Biomol (Plymouth Meeting, Pa.).
    •  FIGURES
  • The data represents mean±S.D. of triplicate samples of an experiment repeated at least three times. *=Statistically significant (p<0.05) in comparison to LPS (positive control). [0065]
  • FIGS. [0066] 1A-E Legend
  • Microglia were treated with 100 ng/ml of LPS for various periods of time following which A-D. cPLA[0067] 2 distribution was assessed by indirect immunofluorescence (1A) control , (1B) LPS-15 min, (1C) LPS-15 min, (1D) LPS-60 min, (1E) whole cell lysates were prepared and run on SDS-PAGE, transferred and probed with a cPLA2 antibody.
  • FIGS. [0068] 2A-D Legend
  • 5-lipoxygnease inhibitor (NDGA, [0069] 2A) and 5-lipoxygenase activating protein inhibitor (para-REV5901, 2B) significantly inhibited TNF-alpha release, however, COX-2 inhibitors Ibuprofen (2C), Vioxx (2D), and Celebrex (2D) failed to produce any reduction in TNF-alpha release in rat primary microglia cells following LPS activation.
  • FIGS. [0070] 3A-B Legend
  • cPLA2 inhibitors ATFMK ([0071] 3A) and BMS-229724 (3B) significantly inhibited TNF-alpha release in rat primary microglia cells following LPS activation.
  • FIGS. [0072] 4A-C Legend
  • cPLA2 inhibitor, ATFMK ([0073] 4A) and FLAP inhibitor, para-REV5901 (4B) significantly inhibited nitrite release in rat primary microglia cells following LPS activation. However, COX-2 inhibitor, Celebrex (4C) had no effect on nitrite release.
  • FIGS. [0074] 5A-B Legend
  • Effects of NF-κB inhibitors, BAY 11-7085 and SN-50 on TNFα and NO release in LPS treated microglia. Microglia were treated with various concentrations of either BAY- or SN-50 for one hour prior to the addition of LPS. Twenty-four hours post LPS challenge the media was assayed for TNFα release by ELISA ([0075] 5A) and nitrite release by modified Greiss reagent (5B).
  • FIGS. [0076] 6A-C Legend
  • Effects of cPLA[0077] 2 and 5-LOX inhibitors on LPS mediated IκBα degradation. Microglia were treated with 100 ng/ml of LPS for various periods of time following which whole cell lysates were prepared and run on SDS-PAGE, transferred and probed with a IκBα antibody as mentioned in immunoblotting. (6A) 10 ng/ml LPS alone, (6B) LPS+10 μM ATFMK, (6C) LPS+50 μM L-655,238.
  • FIGS. [0078] 7 A-D Legend
  • Effects of cPLA[0079] 2 and 5-LOX inhibitors on LPS mediated NF-κB translocation. Microglia were treated with 100 ng/ml of LPS. for various periods of time following which p65 distribution was assessed by indirect immunofluorescence (7A) control, (7B) LPS-5 min., (7C) LPS+10 μM ATFMK-5 min., (7D) LPS+50 μM L-655,238-5 min. (7E) LPS+NDGA-20 μM-5 min.

Claims (5)

What is claimed is:
1. A method of modulating microglia activation comprising the administration to a human in need thereof an effective amount of
Figure US20030045566A1-20030306-C00004
or a pharmaceutically acceptable salt or solvate thereof.
2. A method of inhibiting the release of pro-inflammatory substances from activated microglial cells comprising the administration to a human in need thereof an effective amount of
Figure US20030045566A1-20030306-C00005
or a pharmaceutically acceptable salt or solvate thereof.
3. A method of treating a disorder selected from the group consisting of Alzheimer's disease, traumatic brain injury, brain ischemia and subarachanoid hemmorhage comprising the administration to a human in need thereof an effective amount of
Figure US20030045566A1-20030306-C00006
or a pharmaceutically acceptable salt or solvate thereof.
4. A method of attenuating degradation of IκBα comprising the administration to a human in need thereof an effective amount of
Figure US20030045566A1-20030306-C00007
or a pharmaceutically acceptable salt or solvate thereof.
5. A method of inhibiting nuclear translocation of the NF-κB active complex comprising the administration to a human in need thereof an effective amount of
Figure US20030045566A1-20030306-C00008
or a pharmaceutically acceptable salt or solvate thereof.
US10/274,587 2000-07-13 2002-10-21 Method of modulating microglial activation for the treatment of acute and chronic neurodegenerative disorders Abandoned US20030045566A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/274,587 US20030045566A1 (en) 2000-07-13 2002-10-21 Method of modulating microglial activation for the treatment of acute and chronic neurodegenerative disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21808500P 2000-07-13 2000-07-13
US26133201P 2001-01-12 2001-01-12
US09/899,657 US6545019B2 (en) 2000-07-13 2001-07-05 Method of modulating microglial activation for the treatment of acute and chronic neurodegenerative disorders
US10/274,587 US20030045566A1 (en) 2000-07-13 2002-10-21 Method of modulating microglial activation for the treatment of acute and chronic neurodegenerative disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/899,657 Division US6545019B2 (en) 2000-07-13 2001-07-05 Method of modulating microglial activation for the treatment of acute and chronic neurodegenerative disorders

Publications (1)

Publication Number Publication Date
US20030045566A1 true US20030045566A1 (en) 2003-03-06

Family

ID=26912541

Family Applications (4)

Application Number Title Priority Date Filing Date
US09/899,657 Expired - Fee Related US6545019B2 (en) 2000-07-13 2001-07-05 Method of modulating microglial activation for the treatment of acute and chronic neurodegenerative disorders
US10/272,815 Abandoned US20030050322A1 (en) 2000-07-13 2002-10-17 Method of modulating microglial activation for the treatment of acute and chronic neurodegenerative disorders
US10/272,816 Abandoned US20030045570A1 (en) 2000-07-13 2002-10-17 Method of modulating microglial activation for the treatment of acute and chronic neurodegenerative disorders
US10/274,587 Abandoned US20030045566A1 (en) 2000-07-13 2002-10-21 Method of modulating microglial activation for the treatment of acute and chronic neurodegenerative disorders

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US09/899,657 Expired - Fee Related US6545019B2 (en) 2000-07-13 2001-07-05 Method of modulating microglial activation for the treatment of acute and chronic neurodegenerative disorders
US10/272,815 Abandoned US20030050322A1 (en) 2000-07-13 2002-10-17 Method of modulating microglial activation for the treatment of acute and chronic neurodegenerative disorders
US10/272,816 Abandoned US20030045570A1 (en) 2000-07-13 2002-10-17 Method of modulating microglial activation for the treatment of acute and chronic neurodegenerative disorders

Country Status (3)

Country Link
US (4) US6545019B2 (en)
AU (1) AU2002222910A1 (en)
WO (1) WO2002005825A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7640062B2 (en) 2000-05-08 2009-12-29 Brainsgate Ltd. Methods and systems for management of alzheimer's disease
US7146209B2 (en) * 2000-05-08 2006-12-05 Brainsgate, Ltd. Stimulation for treating eye pathologies
WO2003039557A1 (en) 2001-11-02 2003-05-15 The Regents Of The University Of California Methods and compositions for prevention and treatment of inflammatory disease, autoimmune disease, and transplant rejection
US7684859B2 (en) * 2002-04-25 2010-03-23 Brainsgate Ltd. Stimulation of the OTIC ganglion for treating medical conditions
JP2006500318A (en) * 2002-04-25 2006-01-05 ブレインスゲート リミテッド Method and apparatus for adjusting the characteristics of BBB and cerebral circulation using nerve excitatory and / or neurosuppressive effects of odorants on the intracranial nerve
AU2003237379A1 (en) * 2002-06-10 2003-12-22 Oklahoma Medical Research Foundation A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system
US7507531B2 (en) 2002-10-17 2009-03-24 Decode Genetics Chf. Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
US7851486B2 (en) 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
EP1585430B1 (en) * 2002-11-14 2017-01-11 Brainsgate Ltd. Surgical tools and techniques for stimulation
US7728036B2 (en) 2003-05-20 2010-06-01 Erimos Pharmaceuticals, Llc Methods for delivery of catecholic butanes for treatment of tumors
JP2006528700A (en) * 2003-05-20 2006-12-21 エリモス・ファーマスーティカルズ・エルエルシー Methods and compositions for administration of catecholbutane for the treatment of obesity
US20060141029A1 (en) * 2003-05-20 2006-06-29 Erimos Pharmaceuticals Llc Methods and compositions for delivery of catecholic butanes for treatment of diseases
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
US8010189B2 (en) * 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
CN100440843C (en) * 2004-05-12 2008-12-03 华为技术有限公司 Ring net and method for realizing service
US8440648B2 (en) * 2004-07-20 2013-05-14 Erimos Pharmaceuticals Llc Methods and compositions for treatment of intraepithelial neoplasia
US20090299418A1 (en) * 2004-08-23 2009-12-03 Brainsgate Ltd. Concurrent bilateral spg modulation
ES2536177T3 (en) * 2005-01-27 2015-05-21 Erimos Pharmaceuticals Llc Formulations for the injection of catecholic butanes, including NDGA compounds, in animals
KR100679306B1 (en) * 2005-03-31 2007-02-06 아미코젠주식회사 Pharmaceutical composition for the treatment or prevention of cranial nerve disease containing lignan compound
KR20090006062A (en) * 2006-02-23 2009-01-14 에리모스 파마슈티컬스 엘엘씨 How to treat influenza virus infection
US20090210026A1 (en) * 2006-08-17 2009-08-20 Brainsgate Ltd. Spg stimulation for enhancing neurogenesis and brain metabolism
US9067875B2 (en) 2006-10-02 2015-06-30 Erimos Pharmaceuticals Llc Tetra-substituted NDGA derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use
WO2008042896A2 (en) * 2006-10-02 2008-04-10 Erimos Pharmaceuticals Llc Tetra-substituted ndga derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use
WO2008067566A1 (en) 2006-11-30 2008-06-05 Amira Pharmaceuticals, Inc. Compositions and treatments comprising 5-lipoxygenase-activating protein inhibitors and nitric oxide modulators
US7860569B2 (en) 2007-10-18 2010-12-28 Brainsgate, Ltd. Long-term SPG stimulation therapy for prevention of vascular dementia
US9550827B2 (en) * 2007-10-19 2017-01-24 The Regents Of The University Of California Methods for ameliorating and preventing central nervous system inflammation
US8193730B2 (en) 2008-06-12 2012-06-05 3M Innovative Properties Company Dimmer and illumination apparatus with amplitude ordered illumination of multiple strings of multiple color light emitting devices
US20130310421A1 (en) * 2012-05-18 2013-11-21 Temple University - Of The Commonwealth System Of Higher Education Treatment of amyloid beta amyloidosis
US20150322049A1 (en) * 2012-12-13 2015-11-12 Ludwig Aigner Leukotriene pathway antagonists for the treatment of dementia, cognitive deficits in parkinson's disease and/or learning and memory deficiencies in parkinson's disease
EP2878335B1 (en) 2013-11-10 2018-01-03 Brainsgate Ltd. Implant and delivery system for neural stimulator
ES2878405T3 (en) * 2014-02-04 2021-11-18 Bioscience Pharma Partners Llc Use of flap inhibitors to reduce neuroinflammation-mediated injury in the central nervous system
US10271907B2 (en) 2015-05-13 2019-04-30 Brainsgate Ltd. Implant and delivery system for neural stimulator
CN114949010A (en) * 2021-12-30 2022-08-30 九江学院 Application of fructus akebiae extract and separation part thereof in product for preventing or treating neuroinflammation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6111796A (en) * 1995-06-12 1997-01-09 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5 -lipoxygenase inhibitor

Also Published As

Publication number Publication date
US20030045570A1 (en) 2003-03-06
AU2002222910A1 (en) 2002-01-30
US20030050322A1 (en) 2003-03-13
US6545019B2 (en) 2003-04-08
WO2002005825A1 (en) 2002-01-24
US20020022650A1 (en) 2002-02-21

Similar Documents

Publication Publication Date Title
US6545019B2 (en) Method of modulating microglial activation for the treatment of acute and chronic neurodegenerative disorders
Liu et al. Harmine ameliorates cognitive impairment by inhibiting NLRP3 inflammasome activation and enhancing the BDNF/TrkB signaling pathway in STZ-induced diabetic rats
Yang et al. Ginsenoside Rg1 improves Alzheimer's disease by regulating oxidative stress, apoptosis, and neuroinflammation through Wnt/GSK‐3β/β‐catenin signaling pathway
Jang et al. β-Amyloid-induced apoptosis is associated with cyclooxygenase-2 up-regulation via the mitogen-activated protein kinase–NF-κB signaling pathway
Jana et al. Fibrillar amyloid-β-activated human astroglia kill primary human neurons via neutral sphingomyelinase: implications for Alzheimer's disease
Lee et al. Genetic deletion of soluble epoxide hydrolase delays the progression of Alzheimer’s disease
Craft et al. Aminopyridazines inhibit β-amyloid-induced glial activation and neuronal damage in vivo
Wei et al. Epigallocatechin gallate attenuates amyloid β-induced inflammation and neurotoxicity in EOC 13.31 microglia
Yan et al. Abnormal mitochondrial quality control in neurodegenerative diseases
Tolón et al. The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages
Lin et al. 3, 6’-dithiopomalidomide reduces neural loss, inflammation, behavioral deficits in brain injury and microglial activation
Esposito et al. Cannabidiol in vivo blunts β‐amyloid induced neuroinflammation by suppressing IL‐1β and iNOS expression
Wang et al. Hydrogen gas attenuates hypoxic‐ischemic brain injury via regulation of the MAPK/HO‐1/PGC‐1a pathway in neonatal rats
Dewapriya et al. Neoechinulin A suppresses amyloid-β oligomer-induced microglia activation and thereby protects PC-12 cells from inflammation-mediated toxicity
Rahimian et al. Tropisetron attenuates amyloid‐beta‐induced inflammatory and apoptotic responses in rats
Li et al. Zerumbone ameliorates behavioral impairments and neuropathology in transgenic APP/PS1 mice by suppressing MAPK signaling
Liu et al. A novel nicotinic mechanism underlies β-amyloid-induced neurotoxicity
Fang et al. Neurotropin® alleviates hippocampal neuron damage through a HIF‐1α/MAPK pathway
Yenki et al. Inhibition of phosphorylation of JNK suppresses Aβ-induced ER stress and upregulates prosurvival mitochondrial proteins in rat hippocampus
Yan et al. MAPKs and NF‐κB‐mediated acrylamide‐induced neuropathy in rat striatum and human neuroblastoma cells SY5Y
Zhu et al. Blueberry opposes β-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activation protein kinase
Li et al. Macrophage colony stimulatory factor and interferon‐γ trigger distinct mechanisms for augmentation of β‐amyloid‐induced microglia‐mediated neurotoxicity
Yoon et al. Okadaic acid induces JNK activation, bim overexpression and mitochondrial dysfunction in cultured rat cortical neurons
JP7417217B2 (en) Aβ-induced damage inhibitor or reducer
JP2022527329A (en) Aminoguanidine hydrazone as a retromer stabilizer useful for treating neurological disorders

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION